By otakuyassine3@gmail.com 
Insmed Incorporated (NASDAQ:INSM – Get Free Report) COO Roger Adsett sold 1,457 shares of the company’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $68.72, for a total transaction of $100,125.04. Following the completion of the transaction, the chief operating officer now owns 146,082 shares in the company, valued at approximately $10,038,755.04. This represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Roger Adsett also recently made the following trade(s):
- On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The stock was sold at an average price of $63.68, for a total transaction of $312,159.36.
- On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80.
Insmed Price Performance
Shares of INSM traded up $2.55 during trading hours on Thursday, reaching $72.75. The stock had a trading volume of 2,264,024 shares, compared to its average volume of 2,139,833. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The stock has a market capitalization of $13.01 billion, a PE ratio of -13.11 and a beta of 1.12. The company’s 50-day moving average is $71.18 and its two-hundred day moving average is $72.47.
Insmed (NASDAQ:INSM – Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. The business’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.10) EPS. Research analysts expect that Insmed Incorporated will post -5.44 EPS for the current year.
Wall Street Analysts Forecast Growth
INSM has been the topic of a number of recent research reports. Bank of America increased their target price on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. JPMorgan Chase & Co. increased their price objective on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, November 22nd. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Finally, Truist Financial reaffirmed a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $83.67.
Get Our Latest Analysis on INSM
Hedge Funds Weigh In On Insmed
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC acquired a new position in shares of Insmed in the 3rd quarter worth approximately $30,000. GAMMA Investing LLC lifted its holdings in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares during the period. Exchange Traded Concepts LLC boosted its position in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares during the last quarter. JCIC Asset Management Inc. acquired a new stake in Insmed during the 3rd quarter worth about $133,000. Finally, Quantbot Technologies LP bought a new position in shares of Insmed in the 3rd quarter worth about $133,000.
Insmed Company Profile
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Articles
Receive News & Ratings for Insmed Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Insmed and related companies with MarketBeat.com’s FREE daily email newsletter.